Skip to content

Safety and Efficacy of Wendan Decoction in Acute Moderated to Severe Brain Injury

A Randomized Controlled Trial of Wendan Decoction as a Palliative Treatment for Acute Brain Injury

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03851809
Enrollment
60
Registered
2019-02-22
Start date
2014-06-01
Completion date
2016-01-31
Last updated
2019-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Brain Injury

Keywords

traditional chinese medicine combination treatment

Brief summary

Efficacy and safety of Traditional Chinese Medicine (Wendan decoction) combined with conventional neurologic intensive care in patients with acute moderated to severe brain injury in early stage - A randomized controlled study.

Detailed description

This study adopted a prospective, randomized controlled design. All eligible patients included in the study agreed to participated and signed the informed consent from and the study procedures were approved by the ethical committee of Taichung Tzu Chi general hospital (REC103-26). Patients were recruited from the neurosurgery department of Taichung Tzu Chi general hospital between June 2014 and July 2015. A total of 60 patients were enrolled in this study and randomized into intervention group and control group. All patients of both groups were enrolled within 14 days after episode and a follow-up interview until 6 months from the onset. The intervention group mean regular neuro-intensive care combined TCM and the intervention group mean only neuro-intensive care. But there are 7 patients in intervention group and 12 patients in control group quit out this study

Interventions

DRUGWendan decoction combination in acute brain injury

In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.

Sponsors

Taichung Tzu Chi Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

no masking design

Intervention model description

randomized clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* traumatic brain injury or spontaneously intracerebral hemorrhage within 14 days of onset; * an initial score of 3-12 points of GCS score; * adults between 18 to 80 years old; * and signed informed consent form.

Exclusion criteria

* after 14 days of onset; * a history of previous TBI or stroke; * intracranial aneurysm or arteriovenous malformation ruptured; * combination other major organ injury (heart, lung, intra-abdomen organ, pelvic fracture, major vessels); * other severe disease such as heart or kidney failure; * previous diagnosed cancer; and pregnant women.

Design outcomes

Primary

MeasureTime frameDescription
mortality1 monthbetween 1 month mortality
ICU stay1 monthhow many days of ICU stay
Glasgow coma scale1 monthfrom 3 to 15 , higher value indicate better outcome
Disability rating scale1 monthfrom 0 to 29 , higher value mean worse outcome
modified Rankin scale1 monthfrom 0 to 6 , 0 mean normal and 6 mean dead , higher value indicated worse outcome
Ventilator use1 monthhow many days of ventilator use

Secondary

MeasureTime frameDescription
modified Rankin scale6 monthfrom 0 to 6 , 0 mean normal and 6 mean dead , higher value indicated worse outcome
Disability rating scale6 monthfrom 0 to 29 , higher value mean worse outcome
Barthel index6 monthsfrom 0 to 100 , higher value mean independency daily life care and better outcome
Glasgow coma scale6 monthfrom 3 to 15 , higher value indicate better outcome

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026